Life-threatening COVID-19 presenting as stroke with antiphospholipid antibodies and low ADAMTS-13 activity, and the role of therapeutic plasma exchange: A case series

Abdulrahman Alharthy1, Fahad Faqhi1, Abdullah Balhamar1, Ziad A Memish2 and Dimitrios Karakitsos1

Abstract
We present a case series of three patients with COVID-19 who were admitted to our intensive care unit due to acute respiratory distress syndrome, brain infarction, pulmonary embolism, and antiphospholipid antibodies. We applied therapeutic plasma exchange on all cases. On intensive care unit admission, all patients had low (<10) Glasgow Coma Scale, and central nervous imaging showed multiple brain infarctions. COVID-19 was confirmed by reverse transcriptase polymerase chain reaction assays. Patients underwent rescue therapeutic plasma exchange using the Spectra OptiaTM Apheresis System (Terumo BCT Inc., USA), which operates with acid-citrate dextrose anticoagulant as per Kidney Disease Improving Global Outcomes 2019 guidelines. A dose of 1.5 plasma volume was used for the first dose and then 1 plasma volume daily for a total of five doses. Plasma was replaced with Octaplas LG® (Octapharma AG, USA), which is an artificial fresh frozen plasma product that has undergone viral inactivation by prion reduction technology. We administered ARDS-net/prone positioning ventilation, empiric antiviral treatment, therapeutic anticoagulation, and intensive care unit supportive care. Laboratory tests showed lymphocytopenia; elevated levels of D-dimer, fibrinogen, total bilirubin, C-reactive protein, lactate dehydrogenase, and ferritin; as well as low levels of ADAMTS-13 activity and antibody. Serology tests depicted positive IgM and IgG antiphospholipid antibodies (anti-cardiolipin and anti-β2-glycoprotein I antibodies). No side effects of therapeutic plasma exchange were recorded. After the completion of therapeutic plasma exchange, patients improved clinically and gradually recovered neurologically (after 27–32 days). To conclude, in life-threatening COVID-19, especially when immune dysregulation features such as antiphospholipid antibodies exist, therapeutic plasma exchange could be an effective rescue therapy.

Keywords
COVID-19, antiphospholipid antibodies, brain infarction, ADAMTS-13 activity, therapeutic plasma exchange, artificial plasma

Date received: 27 July 2020; accepted: 10 September 2020

Introduction
The novel SARS-CoV-2 (COVID-19) pandemic emerged from Wuhan, China, and spread worldwide.1 Most patients with COVID-19 are asymptomatic; however, a minority of cases can present with life-threatening diseases, which are characterized by acute respiratory distress syndrome (ARDS), sepsis, multi-system organ failure (MSOF), cytokine release syndrome (CRS), neurological manifestations, and thromboembolic disease.2–4 Recently, severe COVID-19 was associated with devastating central nervous system (CNS) pathology, including stroke, and acute disseminated encephalomyelitis.5 Moreover, severe thromboembolic phenomena were observed in mechanically ventilated critically ill patients.

1Critical Care Department, King Saud Medical City, Riyadh, Saudi Arabia
2Research and Innovation Center, King Saud Medical City, Riyadh, Saudi Arabia

Corresponding Author:
Dimitrios Karakitsos, Critical Care Department, King Saud Medical City, PO Box 331905, Shemaisi, Riyadh 11373, Saudi Arabia.
Email: karakitsosdimitrios@gmail.com
with COVID-19.6–10 The clinically observed thrombotic microangiopathy in COVID-19 was further confirmed by the pathology results of post-mortem studies.11,12 Also, this vasculopathy in COVID-19 has a comparable thrombotic phenotype and inflammatory profile (i.e. elevated C-reactive protein, D-dimers, ferritin, lactate dehydrogenase, and interleukin-6) with thrombotic microangiopathies such as thrombotic thrombocytopenic purpura.

The rationale for using therapeutic plasma exchange (TPE) as an adjunctive rescue therapy in life-threatening COVID-19 is that TPE can reduce the hyperinflammation associated with COVID-19, thus ameliorating the microangiopathy and preventing the evolution of MSOF. TPE, without protective antibodies, has been previously used with variable success in patients with severe sepsis, MSOF, and fulminant SARS-CoV, although its benefit remains undetermined in severe ARDS.11,14 In a recent pilot study, our group showed that the application of TPE early in the course of life-threatening COVID-19 resulted in a reduction in inflammatory biomarkers and a favorable clinical outcome.15 Herein, we briefly discuss three COVID-19 patients who presented with ARDS, thromboembolic disease, brain infarction, and antiphospholipid antibodies.

### Case

We present three patients who were admitted to our COVID-19 designated intensive care unit (ICU) due to ARDS, thromboembolic disease, and low Glasgow Coma Scale (GCS). The inclusion criteria for the application of TPE as rescue therapy in life-threatening COVID-19 are detailed elsewhere.16 Briefly, adult (<18 years old) mechanically ventilated patients with confirmed SARS-CoV-2 infection and life-threatening features such as ARDS (according to the Berlin criteria), Acute Physiology and Chronic Health Evaluation II score ⩾20, severe sepsis/septic shock, MSOF, and associated CRS were eligible for TPE.16 CRS was defined based on the criteria outlined in Table 1.

SARS-CoV-2 infection was confirmed by reverse transcriptase polymerase chain reaction (RT-PCR) assays performed on nasopharyngeal swabs using QuantiNova Probe RT-PCR kit (Qiagen) in a Light-Cycler 480 real-time PCR system (Roche, Basel, Switzerland).17,18 Upon ICU admission, CNS computed tomography (CT) scan and CT angiography revealed multiple diffuse brain infarctions, which were consistent with a microangiopathic pattern in all patients. Following written informed consent obtained by their legal representatives, the patients underwent rescue TPE, without protective antibodies. TPE was initiated 24–48 h after ICU admission, using the Spectra Optia™ Apheresis System (Terumo BCT Inc., USA), which operates with acid-citrate dextrose anticoagulant as per Kidney Disease Improving Global Outcomes 2019 guidelines.19,20 A dose of 1.5 plasma volume was used for the first dose and then 1 plasma volume daily for a total of five doses (4 h/day). Intravenous calcium replacement, hydrocortisone 100 mg, and chlorpheniramine 10 mg were administered during TPE to reduce any potential side effects. Plasma was replaced with artificial Octaplas LG® (Octapharma AG, USA), which is a fresh frozen pooled plasma product that has undergone viral inactivation by prion reduction technology.21

The main characteristics and laboratory findings of our patients are summarized in Table 2. On ICU admission, they presented with ARDS, pulmonary embolism, and GCS <10. We administered ARDS-net/prone positioning ventilation, empiric treatment with ribavirin, interferon beta-1b, therapeutic anticoagulation (enoxaparin adjusted per body weight and renal function), and ICU supportive care.22 No other putative immunomodulatory therapies such as tocilizumab were administered. Echocardiography and cardiac enzymes were normal. Baseline laboratory findings were lymphocytopenia, increased D-dimers, fibrinogen, and low levels of ADAMTS-13 activity/antibody (TECHNOZYM® ELISA).23 Also, patients had increased levels of total bilirubin, C-reactive protein, lactate dehydrogenase, and ferritin (Table 2). Notably, follow-up serology tests, which were performed once, depicted IgM and IgG antiphospholipid antibodies (anti-cardiolipin and anti-β2-glycoprotein I antibodies). Lupus anticoagulant was not detected although the tests were carried out in the acute phase of the disease.

After five TPE sessions, no side effects of treatment such as coagulopathy, infection, and allergies were recorded. Sequential Organ Function Assessment (SOFA) scores from 8 to 9 (baseline) were reduced to <4 post-TPE. Partial arterial pressure of oxygen to fractional inspired concentration of oxygen (SPO2 to FiO2) ratios from 120 to 140 (baseline) increased to >300 post-TPE; hence, all patients were gradually weaned off the mechanical ventilation. All inflammatory biomarkers and lymphocyte counts were equally normalized post-TPE. ADAMTS-13 activity from 8% to 15% (baseline) increased to 22% to 28% post-TPE. All patients gradually recovered and neurologically improved (GCS >10); hence, they were all discharged to step-down units for rehabilitation. The ICU length of stay was 27–32 days (Table 2). RT-PCR for COVID-19 and microbiology were negative 30 days post-ICU admission.

### Table 1. Criteria for defining CRS in COVID-19.

| Criterion | Definition |
|-----------|------------|
| C-reactive protein | >100 or >50 mg/L but doubled in the past 48 h |
| Lymphocyte count | <0.6 × 10⁹/L |
| Serum interleukin-6 | IL-6 ⩾3 × upper normal limit |
| Ferritin | >300 µg/L (or surrogate) with doubling within 24 h |
| Ferritin | >600 µg/L at presentation and LDH >250 U/L |
| Elevated D-dimer | >1 µg/mL |

CRS: cytokine release syndrome; LDH: lactate dehydrogenase.

*We define the presence of one criterion for developing CRS as low risk, the presence of two to three criteria as moderate risk, and the presence of more than three criteria as high risk.
Table 2. Characteristics, laboratory findings, and outcome measures of patients with COVID-19.

| Characteristic                                               | Patient 1                          | Patient 2                          | Patient 3                          |
|-------------------------------------------------------------|------------------------------------|------------------------------------|------------------------------------|
| Demographic characteristics                                |                                    |                                    |                                    |
| Age (years)                                                 | 65                                 | 49                                 | 62                                 |
| Sex                                                         | Male                               | Male                               | Female                             |
| Nationality                                                 | Asian                              | Asian                              | Middle Eastern                      |
| Baseline features                                           |                                    |                                    |                                    |
| Medical history                                             | Hypertension, Diabetes             | Previously healthy                 | Hypertension, diabetes             |
| Symptoms prior to hospital admission                        | Fever, persistent cough, myalgias,| Fever, persistent cough, headache,| Fever, persistent cough, diarrhea,|
|                                                             | dyspnea                            | anosmia                            | headache                           |
| Duration of symptoms (days)                                 | 7                                  | 5                                  | 8                                  |
| Cluster infection (Yes/No)                                  | No                                 | Yes                                | No                                 |
| Baseline chest imaging findings                             | Bilateral opacities/infiltrates    | Bilateral opacities/infiltrates    | Bilateral opacities/infiltrates    |
|                                                             | and subsegmental pulmonary        | and subsegmental pulmonary        | and subsegmental pulmonary        |
|                                                             | embolism                           | embolism                           | embolism                           |
| Deep vein thrombosis (Doppler sonography)                   | Yes                                | No                                 | No                                 |
| Days from disease onset to thrombotic event                 | 8                                  | 6                                  | 10                                 |
| Findings on intensive care unit admission                   |                                    |                                    |                                    |
| Days since disease onset                                    | 10                                 | 9                                  | 12                                 |
| Sequential Organ Function Assessment score                  | 9                                  | 9                                  | 8                                  |
| Acute Physiology and Chronic Health Evaluation II score      | 21                                 | 22                                 | 21                                 |
| Partial arterial pressure of oxygen to fractional inspired  | 120                                | 120                                | 140                                |
| concentration of oxygen                                     |                                    |                                    |                                    |
| Mechanical ventilation (Yes/No)                             | Yes                                | Yes                                | Yes                                |
| Laboratory findings                                         |                                    |                                    |                                    |
| White cell count (per mm$^3$)                               | 12,270                             | 9980                               | 10,320                             |
| Total neutrophils                                           | 11,200                             | 9,102                              | 9,450                              |
| Total lymphocytes                                           | 210                                | 190                                | 230                                |
| Platelet count (per mm$^3$)                                 | 102,000                            | 101,900                            | 150,240                            |
| Hemoglobin (g/L)                                            | 112                                | 116                                | 109                                |
| Albumin (g/L)                                               | 25.7                               | 24.8                               | 23.2                               |
| Alanine aminotransferase (U/L)                              | 45                                 | 62                                 | 34                                 |
| Aspartate aminotransferase (U/L)                            | 51                                 | 78                                 | 44                                 |
| Total bilirubin (μmol/L)                                    | 24                                 | 28                                 | 27                                 |
| Creatine kinase (U/L)                                       | 84                                 | 121                                | 97                                 |
| Creatinine (μmol/L)                                         | 74                                 | 71                                 | 59                                 |
| High-sensitivity cardiac troponin I (pg/mL)                 | 6.3                                | 4.1                                | 5.9                                |

(Continued)
### Table 2. (Continued)

| Characteristic                          | Patient 1 | Patient 2 | Patient 3 |
|----------------------------------------|-----------|-----------|-----------|
| Prothrombin time (s)                   | 15.2      | 15.9      | 15.5      |
| Activated partial-thromboplastin time (s) | 45.1      | 44.8      | 47.1      |
| Fibrinogen (g/L)                       | 4.23      | 4.78      | 4.09      |
| Fibrin degradation products (mg/L)     | 29.7      | 20.1      | 30.8      |
| D-dimer (mg/L)                         | 13.2      | 12.1      | 11.9      |
| ADAMTS 13 activity (%)                 | 10%       | 8%        | 15%       |
| ADAMTS 13 IgG (U/L)                    | 10        | 7         | 11        |
| Serum ferritin (μg/L)                  | 778       | 1006      | 1289      |
| High-sensitivity C-reactive protein (mg/L) | 142      | 201       | 169       |
| Antiphospholipid antibodies<sup>a</sup> | Anticardiolipin, anti-β2-glycoprotein IgM, and IgG | Anticardiolipin, anti-β2-glycoprotein IgM, and IgG | Anticardiolipin, anti-β2-glycoprotein IgM, and IgG |
| Central nervous system imaging features | Multiple cerebral infarctions in bilateral frontal/parietal lobes and bilateral cerebellar hemispheres | Multiple cerebral infarctions in bilateral frontal/parietal lobes | Right middle cerebral artery infarction and bilateral occipital lobe infarctions |
| Intensive care unit therapy            | Ribavirin, antibiotics, therapeutic anticoagulation | Ribavirin, antibiotics, therapeutic anticoagulation | Ribavirin, antibiotics, therapeutic anticoagulation |
| Plasma exchange without therapeutic antibodies (sessions) | 5 | 5 | 5 |
| Outcome measures                       |           |           |           |
| Days on mechanical ventilation         | 18        | 20        | 22        |
| Intensive care unit length of stay (days) | 27        | 30        | 32        |
| Secondary bacterial infection (Yes/No)  | No        | No        | No        |
| Glasgow Coma Scale upon intensive care unit discharge | 14        | 14        | 13        |
| Hospital length of stay (days)         | 40        | 42        | 48        |

<sup>a</sup>Antiphospholipid antibodies (IgM and IgG): Patient 1: 42 MPL/44 GPL; Patient 2: 44 MPL/46 GPL; Patient 3: 41 MPL/42 GPL. MPL refers to IgM phospholipid units: one MPL unit is 1 µg of IgM antibody; GPL refers to IgG phospholipid units: one GPL unit is 1 µg of IgG antibody. Laboratory reference values: <15.0 MPL or GPL (negative), 15.0–39.9 MPL or GPL (weakly positive), 40.0–79.9 MPL or GPL (positive), and ⩾80.0 MPL or GPL (strongly positive).
Discussion

Life-threatening COVID-19 was linked to the development of CRS, vasculopathy, and CNS pathology.\textsuperscript{2-5,24} The underlying mechanisms of brain infarction in COVID-19 could be indeed versatile as both microangiopathy and large artery disease were reported.\textsuperscript{5} In this case series, follow-up serology tests depicted IgM and IgG antiphospholipid antibodies. These antibodies are characteristic in the diagnosis of antiphospholipid syndrome when at least two elevated measures are depicted 5–6 weeks apart. We were able to measure these antibodies only once; hence, their presence could have been attributed to other putative cofounders such as sepsis, critical illness, and strong immunological responses linked to COVID-19.\textsuperscript{15,25} However, the strict biological diagnosis of CRS in COVID-19 remains debatable.\textsuperscript{26,27} Notwithstanding, the main rationale for applying TPE on COVID-19 is the suppression of thromboinflammation and the amelioration of the ensuing microangiopathy. The latter was partially attributed to the ability of the virus in binding with the angiotensin-converting enzyme 2 (ACE2) receptor, thus causing direct endothelial injury and thromboinflammation, and promoting the dysregulation of the immune and the renin-angiotensin–aldosterone systems.\textsuperscript{28}

Recently, we applied TPE on patients with life-threatening COVID-19 and associated CRS.\textsuperscript{15} We showed that TPE can significantly reduce the levels of inflammatory biomarkers and improve the clinical outcome of critically ill patients with COVID-19 without causing any side effects. Herein, we present three distinct COVID-19 patients who had multiple brain infarctions, coagulopathy with associated antiphospholipid antibodies, and pulmonary embolism. The patients clinically improved after the administration of TPE. Various authors suggested that there is minimal immunosuppression associated with TPE compared to other immunomodulatory therapies, although this issue remains debatable.\textsuperscript{13-16,21,28-31} TPE can discreetly remove significant proportions of interferon-gamma, interleukin-3, -10, -1B, -6, -8, and tumor necrosis factor-alpha.\textsuperscript{13-16,20,28} In this series, no severe coagulopathy or disseminated intravascular coagulation (DIC) was recorded. We showed for the first time, to our knowledge, decreased levels of ADAMTS-13 activity in COVID-19, which were also correlated with progression to MSOF and poor prognosis in sepsis.\textsuperscript{30,32} However, COVID-19-associated coagulopathy has distinct features compared to DIC as the former is mainly associated with increased D-dimer and fibrinogen levels. Thromboembolic disease is more common in COVID-19 compared to sepsis-induced coagulopathy. The present results further supported the notion that COVID-19-associated coagulopathy may exhibit overlapping features of hemophagocytic syndrome, antiphospholipid antibodies, and thrombotic microangiopathy.\textsuperscript{33,34} Also, we used an artificial plasma product as replacement in the TPE regime. The rationale for using this product was its safety profile and reduced high-molecular-weight forms of von Willebrand factor.\textsuperscript{21} TPE with artificial plasma replenishment resulted in a gradual increase in ADAMTS-13 activity and lymphocyte counts, and a subtle decrease in inflammation biomarkers such as lactate dehydrogenase, C-reactive protein, ferritin, and D-dimers in COVID-19 patients. No side effects of TPE such as allergies, coagulopathy, thrombotic events, infections, or deterioration of cardiac or renal function were recorded.

This report, albeit its several limitations that prevents its generalizability, illustrated the beneficial effect of TPE on patients with life-threatening COVID-19 with associated thromboinflammation and CNS pathology. In this case series, brain magnetic resonance imaging could not be performed on admission, thus rendering challenging the differential diagnosis between cerebral microangiopathy and a potentially reversible cerebral vasculitis. The lack of control brain imaging following clinical remission prevented a detailed analysis of the therapeutic results. Also, our patients might have improved due to other empiric treatments, including anticoagulation therapy, which were promptly administered; however, given the severity of their clinical picture, TPE might have helped.\textsuperscript{2,10,35} TPE could be an alternative rescue therapy in severe COVID-19 compared to the more expensive and time-consuming convalescent plasma transfusions that did not show any additional survival benefit in recent trials.\textsuperscript{36} However, the cost and resources of TPE are not negligible. This is why we advocated its use only as rescue therapy. Moreover, the natural course of SARS-CoV-2 viremia is obscure, with conflicting reports suggesting reinfections and/or persistently positive RT-PCR results; hence, the optimal TPE regime and the timing of therapy need to be further elucidated.\textsuperscript{37,38} Nevertheless, we applied TPE early in the course of fulminant COVID-19 to mitigate full-blown CRS and ameliorate the ensuing thromboinflammation, which was characterized by decreased levels of ADAMTS-13 activity. Presumably, at an early stage of COVID-19, dysregulated immune system pathology and associated thromboinflammation may be equally important as viral replication per se.\textsuperscript{39} This might at least partially explain why the administration of low-dose dexamethasone showed a beneficial effect on survival in critically ill patients with COVID-19.\textsuperscript{40}

Conclusion

In life-threatening COVID-19, the underlying mechanisms of brain infarction, low levels of ADAMTS-13 activity, and ensuing thromboinflammation with microangiopathy may be attributed to versatile pathophysiology. TPE may discreetly improve the exaggerated inflammatory immune response and prevent the progression of microangiopathy and organ-related microthrombosis. In life-threatening COVID-19, especially when immune dysregulation features such as antiphospholipid antibodies exist, TPE could be an effective and safe rescue therapy.
Authors' contributions

All authors equally contributed to data acquisition/analysis and drafting this manuscript. All authors reviewed the final version of this manuscript and agree with its submission to the journal.

Declaration of conflicting interests

The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Ethical approval

Ethical approval to report this case series was obtained by the Institutional Review Board of King Saud Medical City, Riyadh, Saudi Arabia (H-01-R-053, IORG0010374#, serial number: H1RI-29-20-01).

Informed consent

Written informed consent was obtained from a legally authorized representative for anonymized patient information to be published in this article.

ORCID iD

Dimitrios Karakitsos https://orcid.org/0000-0003-3370-7099

Data availability

All datasets used in this study are available by the corresponding author upon a reasonable request.

References

1. Guan WJ, Ni ZY, Hu Y, et al. China medical treatment expert group for covid-19 clinical characteristics of coronavirus disease 2019 in China. N Engl J Med 2020; 382(18): 1708–1720.
2. Grasselli G, Zaninelli A, Zanella A, et al. COVID-19 Lombardy ICU network. Baseline characteristics and outcomes of 1591 patients infected with SARS-CoV-2 admitted to ICUs of the Lombardy region, Italy. JAMA 2020; 323(16): 1574–1581.
3. Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet 2020; 395(10229): 1054–1062.
4. Mo P, Xing Y, Xiao Y, et al. Clinical characteristics of refractory COVID-19 pneumonia in Wuhan, China. Clin Infect Dis. Epub ahead of print 16 March 2020; ciaa 270. DOI: 10.1093/cid/ciaa270.
5. Paterson RW, Brown RL, Benjamin L, et al. UCL queen square national hospital for neurology and neurosurgery COVID-19 study group the emerging spectrum of COVID-19 neurology: clinical, radiological and laboratory findings. Brain. Epub ahead of print 8 July 2020; awaa 240. DOI: 10.1093/brain/awaa240.
6. Cui S, Chen S, Li X, et al. Prevalence of venous thromboembolism in patients with severe novel coronavirus pneumonia. J Thromb Haemost 2020; 18(6): 1421–1424.
7. Klok FA, Kruij MJHA, van der Meer NJM, et al. Incidence of thrombotic complications in critically ill ICU patients with COVID-19. Thromb Res 2020; 191: 145–147.
8. Tang N, Bai H, Chen X, et al. Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy. J Thromb Haemost 2020; 18: 1094–1099.
9. Fraissé M, Logre E, Pajot O, et al. Thrombotic and hemorrhagic events in critically ill COVID-19 patients: a French monocenter retrospective study. Critical Care 2020; 24: 245.
10. Panigada M, Bottino N, Tagliabue P, et al. Hypercoagulability of COVID-19 patients in intensive care unit: a report of thromboelastography findings and other parameters of hemostasis. J Thromb Haemost 2020; 18:1738–1742.
11. Deshpande C. Thromboembolic findings in COVID-19 autopsies: pulmonary thrombosis or embolism? Ann Intern Med. Epub ahead of print 15 May 2020. DOI: 10.7326/M20-3255.
12. Fox SE, Akmatbekov A, Harbert JL, et al. Pulmonary and cardiac pathology in African American patients with COVID-19: an autopsy series from New Orleans. Lancet Respir Med 2020; 8(7): 681–686.
13. Dellinger RP, Bagshaw SM, Antonelli M, et al. EUPHRATES trial investigators effect of targeted polymyxin B hemoperfusion on 28-day mortality in patients with septic shock and elevated endotoxin level: the EUPHRATES randomized clinical trial. JAMA 2018; 320(14): 1455–1463.
14. Patel P, Nandvani V, Vanchiere J, et al. Use of therapeutic plasma exchange as a rescue therapy in 2009 pH1N1 influenza A—an associated respiratory failure and hemorrhagic shock. Pediatr Crit Care Med 2011; 12(2): e87–e89.
15. Faqihi A, Alharthy A, Odat M, et al. Therapeutic plasma exchange in adult critically ill patients with life-threatening SARS-CoV-2 disease: a pilot study. J Crit Care 2020; S0883-9441(20)30602-X.
16. Faqihi F, Alharthy A, Alodat M, et al. A pilot study of therapeutic plasma exchange for serious SARS CoV-2 disease (COVID-19): a structured summary of a randomized controlled trial study protocol. Version 2. Trials 2020; 21(1): 506.
17. WHO. Laboratory testing for 2019 novel coronavirus (2019-nCoV) in suspected human cases. Interim Guidance. Epub ahead of print 19 March 2020. https://www.who.int/publications-detail/laboratory-testing-for-2019-novel-coronavirus-in-suspected-human-cases-20200117
18. Chan JF, Yip CC, To KK, et al. Improved molecular diagnosis of COVID-19 by the novel, highly sensitive and specific COVID-19-RdRp/Hel real-time reverse transcription-PCR assay validated in vitro and with clinical specimens. J Clin Microbiol 2020; 58(5): e00310–e00320.
19. Wang AY, Akizawa T, Bavanandan S, et al. 2017 kidney disease: improving global outcomes (KDIGO) chronic kidney disease-mineral and bone disorder (CKD-MBD) guideline update implementation: Asia summit conference report. Kidney Int Rep 2019; 4(11): 1523–1537.
20. Faqihi F, Alharthy A, Alshaya R, et al. Reverse takotsubo cardiomyopathy in fulminant COVID-19 associated with cytokine release syndrome and resolution following therapeutic plasma exchange: a case-report. BMC Cardiovasc Disord 2020; 20(1): 389. DOI: 10.1186/s12872-020-01665-0.
21. Poullin P, Delmotte N, Sanderson F, et al. Efficacy and safety of plasma exchange using a double viral inactivated and prion reduced solvent/detergent fresh frozen plasma for the treatment of thrombotic microangiopathy: the first
French experience in a single center. *Transfus Apher Sci* 2020; 59(1): 102587.

22. Saudi Ministry of Health. Coronavirus diseases 19 (COVID-19) guidelines (Revised Version 1.7). https://covid19.moh.gov.sa (accessed 25 May 2020).

23. Hubbard AR, Heath AB, Kremer Hovinga JA, et al. Establishment of the WHO 1st international standard ADAMTS13, plasma (12/252): communication from the SSC of the ISTH. *J Thromb Haemost* 2015; 13(6): 1151–1153.

24. Varga Z, Flammer AJ, Steiger P, et al. Endothelial cell infection and endotheliitis in COVID-19. *Lancet* 2020; 395(10234): 1417–1418.

25. Zhang Y, Xiao M, Zhang S, et al. Coagulopathy and antiphospholipid antibodies in patients with covid-19. *N Engl J Med* 2020; 382(17): e38.

26. Sinha P, Matthay MA and Calfee CS. Is a “Cytokine Storm” Relevant to COVID-19? *JAMA Intern Med*. Epub ahead of print 30 June 2020. DOI: 10.1001/jamainternalmed.2020.3313.

27. Wu C, Chen X, Cai Y, et al. Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China. *JAMA Intern Med*. Epub ahead of print 13 March 2020. DOI: 10.1001/jamainternalmed.2020.0994.

28. Gupta A, Madhavan MV, Sehgal K, et al. Extrapulmonary manifestations of COVID-19. *Nat Med*. Epub ahead of print 10 July 2020. DOI: 10.1038/s41591-020-0968-3.

29. Keith P, Day M, Choe C, et al. The successful use of therapeutic plasma exchange for severe COVID-19 acute respiratory distress syndrome with multiple organ failure. *SAGE Open Med Case Rep* 2020; 8: 205031X20933473.

30. Stahl K, Schmidt JJ, Seeliger B, et al. Effect of therapeutic plasma exchange on endothelial activation and coagulation-related parameters in septic shock. *Crit Care* 2020; 24(1): 71.

31. Daoud AM, Soliman KM, Ali HK, et al. Potential limitations of plasmapheresis in treatment of COVID-19 patients: how to overcome them? *Ther Apher Dial*. Epub ahead of print 25 July 2020. DOI: 10.1111/1744-9987.13568.

32. Abar J, Castro P, Espinosa G, et al. ADAMTS-13 in critically ill patients with septic syndromes and noninfectious systemic inflammatory response syndrome. *Shock* 2015; 43(6): 556–562.

33. Mei H and Hu Y. Characteristics, causes, diagnosis and treatment of coagulation dysfunction in patients with COVID-19. *Zhonghua Xue Ye Xue Za Zhi* 2020; 41(3): 185–191.

34. Iba T, Levy JH, Connors JM, et al. The unique characteristics of COVID-19 coagulopathy. *Crit Care* 2020; 24(1): 360.

35. Paranjpe I, Fuster V, Lala A, et al. Association of treatment dose anticoagulation with in-Hospital survival among hospitalized patients with COVID-19. *J Am Coll Cardiol* 2020; 76(1): 123–124.

36. Li L, Zhang W, Hu Y, et al. Effect of convalescent plasma therapy on time to clinical improvement in patients with severe and life-threatening COVID-19: a randomized clinical trial. *JAMA* 2020; 324: 1–11.

37. Lan L, Xu D, Ye G, et al. Positive RT-PCR test results in patients recovered from COVID-19. *JAMA* 2020; 323(15): 1502–1503.

38. Zou L, Ruan F, Huang M, et al. SARS-CoV-2 viral load in upper respiratory specimens of infected patients. *N Engl J Med* 2020; 382: 1177–1179.

39. Alharthy A, Faqihi F, Memish ZA, et al. Fragile endothelium and brain dysregulated neurochemical activity in COVID-19. *ACS Chem Neurosci* 2020; 11(15): 2159–2162.

40. RECOVERY Collaborative Group, Horby P, Lim WS, et al. Dexamethasone in hospitalized patients with covid-19—preliminary report. *N Engl J Med*. Epub ahead of print 17 July 2020. DOI: 10.1056/NEJMoa2021436.